Syndax Pharmaceuticals Reports Q3 and FY Results for June 30, 2026

What Happened
Syndax Pharmaceuticals, Inc. announced its financial results for the quarter and fiscal year ended June 30, 2026 via a press release and corporate presentation dated August 4, 2026. The company furnished the press release and presentation as Exhibits 99.1 and 99.2 to its Form 8-K filed on August 4, 2026; the report was signed by CEO Michael A. Metzger.

Key Details

• Filing date: August 4, 2026 (Form 8-K, Item 2.02 and 9.01).
• Reporting period: quarter and year ended June 30, 2026.
• Materials furnished: Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation).
• Form 8-K execution: signed by Michael A. Metzger, Chief Executive Officer.

Why It Matters
Earnings and financial disclosures can move the stock and provide updated information on revenue, cash position, profitability, and business outlook. Syndax’s press release and presentation contain the detailed financial figures and management commentary investors need to assess quarterly results and near-term prospects. Retail investors should review the attached exhibits and any subsequent SEC filings for the specific revenue, expense, cash and guidance figures referenced in the announcement.